| Crohn Disease
Cimzia vs Stelara
Side-by-side clinical, coverage, and cost comparison for crohn disease.Deep comparison between: Cimzia vs Stelara with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsStelara has a higher rate of injection site reactions vs Cimzia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Stelara but not Cimzia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cimzia
Stelara
At A Glance
SC injection
Every 2-4 weeks
TNF-alpha inhibitor
SC injection
Every 8-12 weeks
IL-12/23 antagonist
Indications
- Crohn Disease
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Psoriasis vulgaris
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Crohn Disease
- Ulcerative Colitis
Dosing
Crohn Disease 400 mg SC (two 200 mg injections) at Weeks 0, 2, and 4; maintenance 400 mg every 4 weeks.
Rheumatoid Arthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.
Juvenile polyarthritis Weight-based SC dosing at Weeks 0, 2, and 4, then maintenance every 2 weeks: 100 mg loading / 50 mg maintenance (10 to <20 kg); 200 mg loading / 100 mg maintenance (20 to <40 kg); 400 mg loading / 200 mg maintenance (>=40 kg).
Arthritis, Psoriatic 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.
Ankylosing spondylitis, Non-Radiographic Axial Spondyloarthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks or 400 mg every 4 weeks.
Psoriasis vulgaris 400 mg SC every 2 weeks; for patients <=90 kg, 400 mg at Weeks 0, 2, and 4 followed by 200 mg every 2 weeks may be considered.
Psoriasis vulgaris Adults <=100 kg: 45 mg SC at weeks 0 and 4, then every 12 weeks; adults >100 kg: 90 mg SC at weeks 0 and 4, then every 12 weeks; pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for 60-100 kg, 90 mg for >100 kg) SC at weeks 0 and 4, then every 12 weeks.
Arthritis, Psoriatic Adults: 45 mg SC at weeks 0 and 4, then every 12 weeks (90 mg for >100 kg with co-existent moderate-to-severe plaque psoriasis); pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for >=60 kg, 90 mg for >100 kg with co-existent plaque psoriasis) SC at weeks 0 and 4, then every 12 weeks.
Crohn Disease, Ulcerative Colitis Adults: single IV induction dose (260 mg for <=55 kg, 390 mg for >55-85 kg, 520 mg for >85 kg), followed by 90 mg SC at week 8, then every 8 weeks.
Contraindications
- History of hypersensitivity reaction to certolizumab pegol or any excipient (including angioedema, anaphylaxis, serum sickness, or urticaria)
- Clinically significant hypersensitivity to ustekinumab or any excipient of STELARA
Adverse Reactions
Most common (>=8%) Upper respiratory infections (18%), rash (9%), urinary tract infections (8%)
Serious Serious infections, malignancies, heart failure, hypersensitivity reactions, hepatitis B virus reactivation, neurologic reactions, hematologic reactions, autoimmunity, immunosuppression
Postmarketing Systemic vasculitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, new or worsening psoriasis (all subtypes), lichenoid skin reaction, sarcoidosis, melanoma, Merkel cell carcinoma
Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, headache, fatigue, back pain, dizziness, pharyngolaryngeal pain, pruritus, injection site erythema, myalgia, depression
Serious Infections, malignancies, serious hypersensitivity reactions, posterior reversible encephalopathy syndrome (PRES), noninfectious pneumonia
Postmarketing Hypersensitivity reactions (anaphylaxis, angioedema, dyspnea, rash, urticaria), lower respiratory tract infection, PRES, interstitial pneumonia, eosinophilic pneumonia, cryptogenic organizing pneumonia, pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis
Pharmacology
Certolizumab pegol is a PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody that selectively neutralizes soluble and membrane-associated human TNF-alpha, a key pro-inflammatory cytokine; it lacks an Fc region and therefore does not fix complement or cause antibody-dependent cell-mediated cytotoxicity in vitro.
Ustekinumab is a human IgG1k monoclonal antibody that binds the p40 protein subunit shared by IL-12 and IL-23, blocking their interaction with the IL-12Rb1 receptor chain and thereby suppressing downstream inflammatory signaling involved in natural killer cell activation and CD4+ T-cell differentiation and activation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cimzia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Stelara
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Cimzia
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (7/8)
Stelara
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Cimzia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Stelara
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cimzia.
$5/fillfill
Stelara withMe Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CimziaView full Cimzia profile
StelaraView full Stelara profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.